癌症已成为高收入国家与糖尿病相关的主要死因，需要更多的知识来阐明糖尿病对特定部位癌症的影响。本研究的目的是通过进行全面的系统评价和荟萃分析来评估糖尿病与恶性黑色素瘤之间的关联。使用预先定义的资格标准，对 PubMed、Cochrane 图书馆和 Web of Science 进行了截至 2023 年 2 月 22 日的系统检索。暴露被定义为糖尿病或2型糖尿病，结果被定义为黑色素瘤发病率、黑色素瘤阶段或黑色素瘤特异性死亡率。确定的文章由两名独立评审员进行评估，并使用纽卡斯尔-渥太华观察性研究量表进行质量评估。使用 RevMan 5.4.1 对使用调整风险估计的黑色素瘤风险和使用二分模型对黑色素瘤分期进行荟萃分析。文献检索显示共有 20 项研究符合纳入条件，其中 14 项用于分析黑色素瘤风险，3 项用于分析黑色素瘤厚度和溃疡，4 为黑色素瘤特异性存活。根据荟萃分析，糖尿病不会影响患黑色素瘤的风险（RR：1.05，95％CI：0.99-1.12，p = 0.10）。然而，2 型糖尿病与诊断时更晚期的黑色素瘤阶段相关（Breslow 厚度 > 1 mm：RR 1.35，95% CI：1.22-1.49，p = < 0.001）和溃疡的存在（RR 1.30，95） %CI：1.00-1.68，p = 0.05）。由于研究设计不同，对糖尿病与黑色素瘤特异性死亡率之间的关联进行荟萃分析是不可行的。我们的荟萃分析发现糖尿病与患黑色素瘤的风险之间没有关联，但糖尿病与肿瘤厚度增加和黑色素瘤的存在相关。诊断时有溃疡。需要进一步研究来探索糖尿病黑色素瘤分期与预后之间的关联。PROSPERO ID CRD42023394187.© 2024。作者。

Cancer has become the leading diabetes-related cause of death in high-income countries, and more knowledge is needed to clarify the impact of diabetes on site-specific cancers. The purpose of this study is to assess the association between diabetes and malignant melanoma by conducting a comprehensive systematic review and meta-analysis.Using predefined eligibility criteria, PubMed, The Cochrane Library and Web of Science were systematically searched up to February 22, 2023. Exposure was defined as diabetes or type 2 diabetes and the outcomes were defined as melanoma incidence, melanoma stage or melanoma-specific mortality. The identified articles were evaluated by two independent reviewers and quality assessment was conducted using the Newcastle-Ottawa Scale for observational studies. Meta-analyses were conducted using RevMan 5.4.1 on melanoma risk using adjusted risk estimates and on melanoma stage using a dichotomous model.The literature search revealed 20 studies in total eligible for inclusion, 14 for the analysis of melanoma risk, 3 for melanoma thickness and ulceration, and 4 for melanoma-specific survival. According to the meta-analyses, diabetes did not impact the risk of developing melanoma (RR:1.05, 95%CI:0.99-1.12, p = 0.10). However, type 2 diabetes was associated with more advanced melanoma stages at the time of diagnosis (Breslow-thickness > 1 mm: RR 1.35, 95%CI: 1.22-1.49, p = < 0.001) and presence of ulceration (RR 1.30, 95%CI: 1.00-1.68, p = 0.05). A meta-analysis on the association between diabetes and melanoma-specific mortality was not feasible due to diverse study designs.Our meta-analysis found no association between diabetes and the risk of developing melanoma, but diabetes was associated with increased tumour thickness and the presence of ulceration at the time of diagnosis. Further research is warranted to explore the association between diabetes melanoma stage and prognosis.PROSPERO ID CRD42023394187.© 2024. The Author(s).